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Aims: To compare the burden of disease (BoD) attributable to diabetes expressed in disability-
adjusted life years (DALYs) for five European countries in 2010.
Methods: DALYs lost to diabetes as the sum of years of life lost and years lived with disability 
were estimated by sex and age using country-specific epidemiological data and global disability 
weights. Data from various secondary sources were combined to estimate health loss due to 
diabetes for France, Germany, Italy, Spain, and the UK. National statistical databases were used 
and if necessary, community studies were used to derive the prevalence of diabetes by sex and 
age group, which were weighted proportionately for a national population burden of disease 
estimate. All identified data were adapted to the Global Burden of Disease methodology (2010) 
to calculate the burden attributable to diabetes. No age weighting and discounting was applied. 
Sensitivity to different sources of variation was examined. Germany and Italy lost the largest 
number of DALYs due to diabetes, with 5.9 and 5.8 per 1,000 inhabitants, respectively, followed 
by Spain (4.4), France (3.7), and the UK (2.9). The highest burden was caused by mortality due 
to diabetes, with the exception of the UK, for which the burden due to disability of diabetes 
was higher. Mean DALYs lost were higher for women in Germany, Italy, and Spain and shown 
to increase with age for all countries. Sensitivity analysis in variation in disability weights and 
uncertainty in epidemiological data were shown to have effects on DALYs lost. 
Conclusion: In spite of data limitations, the estimates reported here show that DALY loss 
due to diabetes imposes a substantial burden on countries. Cross-national variation in disease 
epidemiology was the largest source of variation in the burden of diabetes between countries.
Keywords: prevalence, mortality, life expectancy, DALY
Introduction
Diabetes mellitus is a group of metabolic diseases characterized by hyperglycemia 
resulting from defects in insulin secretion, insulin action, or both. There are three major 
types of diabetes: type 1 diabetes, type 2 diabetes, and gestational diabetes. The most 
prevalent are type 1 and 2.
Type 1 diabetes mellitus (T1DM) is produced by the destruction of β cells of the 
pancreas. This leads to insulin deficiency, which can be mild initially, but develops 
quickly towards a complete lack of the hormone. The process is generally rapid in 
infants and children and slow in adults. The velocity of β-cells destruction is variable 
and in case of infants it usually progresses rapidly while this loss is somewhat slower 
in case of adults. A predisposition to develop T1DM is passed through generations in 
families, but the inheritance pattern is unknown. Moreover, there are also environ-
mental factors related to the probability of developing T1DM that are still unclear. 
This type of diabetes accounts for 5%–10% of those diabetics. Generally, people 
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with T1DM  present with acute symptoms of diabetes and 
 markedly elevated blood glucose levels.1
The pathophysiology of type 2 diabetes mellitus (T2DM) 
combines defects that lead finally to hyperglycemia. First of 
all, there is insulin resistance produced in the striated muscle 
(also called peripheral insulin) and insulin resistance produced 
in the liver (also called central insulin resistance). These 
stimulate the production of insulin in the β cells. However, 
since the cells fail to maintain sufficient hormone quantity to 
offset insulin resistance, hyperglycemia arises, which indicates 
failure in insulin secretion. This form of diabetes accounts 
for 90%–95% of those patients with diabetes, but many 
cases remain underdiagnosed until complications appear. At 
the mild stage, controlling diabetes symptoms by making 
changes in the lifestyle is possible. However, as this type of 
diabetes is progressive and chronic, it requires more intensive 
therapy as the disease progresses. Eventually, patients need to 
take medication to keep blood glucose at normal levels.1
Diabetes mellitus is a worldwide problem, which 
accounted for 1.3 million lives in 2008.2 This chronic illness 
requires continuing medical care and patient self- management 
education. In addition to the consequences of abnormal glu-
cose metabolism, diabetes mellitus can lead to long-term 
complications (cardiovascular, peripheral vascular,  ocular, 
neurologic, and renal).3,4 In Europe, there are about 60 million 
people with diabetes, approximately 10.3% of men and 
9.6% of women aged 25 years and over. Across countries, 
Germany, Spain, and Italy were respectively on the second, 
fourth, and fifth position regarding the highest numbers of 
people with diabetes in Europe in 2013.5 Diabetes mellitus 
has been shown to be an expensive condition, costing the 
European Union over €50 billion per year.6,7
The impact of diabetes can be measured by using the 
concept of burden of disease (BoD), which is used to assess 
and compare the relative burden of different conditions by 
quantifying health loss due to the disease and injury that 
remains after treatment, rehabilitation, or prevention efforts 
of the health system and society in general.8 The BoD can be 
measured by cost, morbidity, and mortality. In the last few 
decades, this burden has been increasingly measured across 
nations for comparability purposes.9–12 Disability-adjusted 
life years (DALYs)13 are a measure that combines the concept 
of potential years of life lost due to premature death and years 
of ‘healthy’ life lost in states of less than full health (disability 
states);14 hence, DALYs reflect the burden of a condition and 
facilitate comparisons of different (in theory all) types of 
health conditions or health outcomes. In particular, DALYs 
may be used to include the burden caused by disability and 
chronic diseases in cost-effectiveness studies.15 Compared 
to quality-adjusted life years (QALYs), DALYs permit 
comparisons across different interventions or health areas to 
understand the effectiveness of a portfolio of interventions 
by using a standardized set of disability weights.16
The objective of this study was to carry out a literature 
review to collect data on epidemiology, life expectancy (LE), 
mortality, quality of life (QoL), and disability for DALY 
calculation on diabetes for France, Germany, Italy, Spain, 
and the UK. The data were used to calculate the number of 
DALYs for the total patient population with diabetes for the 
countries of interested by sex and age group and to compare 
between countries for 2010.
Materials and methods
This study used DALYs as a measure of the burden of the 
disease. The DALY is a health gap measure that combines 
information on fatal and nonfatal health outcomes; hence, 
the DALY measures the health loss. The basic assumption 
of DALYs is that similar events would be treated equally in 
all populations to ensure comparability; hence, individual 
characteristics are restricted to age and sex.
This research used the hybrid DALY (H-DALY) approach 
to calculate the DALYs for comparisons.17,18 H-DALYs are 
calculated by adding incidence of years of life lost (YLLs) 
to prevalence of years lived with disability (YLDs), and thus 
quantifies both the BoD occurring during the reference period 
and the burden accrued into the future. The hybrid method is 
a true period-measure because all the data needed to calculate 
H-DALYs can be measured in the time period.
The YLL is the number of years that death occurred 
earlier than the age the person was expected to die if he/she 
had not suffered from the disorder causing death. YLL was 
calculated as follows:
 YLL = D
e
 × L (1)
with D
e
 being the number of deaths related to diabetes as 
the primary cause in a certain time period and L being the 
residual LE at each year of age8 (standard LE when being in 
a certain age category). YLLs were calculated per country, 
age range, and sex.
The YLD is the number of years due to disability and 
is calculated by multiplying the years lost with a disability 
weight reflecting the severity of the condition. YLD is cal-
culated as follows:
 YLD
prevx
 = P
x
 × Dw
x
 (2)
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with P
x
 being the prevalent cases and Dw
x
 being the disability 
weight. From the prevalence and the population data, the 
prevalent cases with diabetes per age category are calculated 
as the outcome of prevalence multiplied by population (total), 
which are calculated per country, age group, and sex.
Then, the DALY formula is as follows:
 DALYs = YLDs 
prevx
 + YLLs (3)
In this study, since the incidence of diabetes was not 
available to calculate the YLDs component of the DALY, an 
incidence-based method was not feasible. Nonetheless, the 
data available on prevalence for diabetes of different age 
categories were available for France, Germany, Italy, Spain, 
and the UK. Moreover, the discounting process is not appli-
cable in this context since this study is a static picture of the 
burden of diabetes in 2010. Finally, no age-weighting factor 
was applied to DALYs, which is similar to the last version 
of the global BoD by Murray et al, which also did not apply 
any age weights.19
The H-DALY avoids both the polio and Elvis problems. 
The polio problem refers to the fact that the incidence is 
captured at a certain point in time and if there are no new 
cases in the next year, the burden might be underestimated. 
The Elvis problem refers to the counterfactual assessment 
that overestimates the prevalence since some cases could be 
diagnosed many years ago.
Moreover, only YLLs were calculated from an incidence 
perspective, which makes it easy to choose death as the event 
and connect all YLLs to the moment of death. The hybrid 
methods consistently combine the projection of the future 
duration of disability (incidence part) and the knowledge 
of deaths that occurred prior to the time period in question 
(prevalence part).
input data
The demographic data on the population size specified by 
age and gender were collected for every country from each 
national statistics database.20–24 Similar to population size 
data, LE (which is not related to any specific disease) by age 
group, and sex were collected for the five countries from their 
national statistics. The epidemiological data with reference 
to prevalence were obtained from each national statistics 
database, except for France (Ricci et al)25 and Germany 
(Heidemann et al).26 Prevalence data for the UK included 
region-specific data for England,27 Scotland,28 Wales,29 and 
Northern Ireland.30 To be able to compare the UK with 
other countries of interest, uniform age categories for the 
 communities within the UK were defined. For the age group 
0–14 years, prevalence data only included T1DM, as no data 
on type 2 diabetes for this age category were  available. It is 
assumed that 97% of the population in this age group was 
suffering from T1DM. The prevalence data were equal for 
boys and girls.
The demographic data on deaths caused by diabetes from 
France,31 Germany,32 Italy,33 Spain,34 and the UK35 were 
obtained. Diabetes mortality rates were obtained by using 
the number of deaths due to diabetes relative to the total 
population. Figures 1 and 2 contain estimations of mortality 
due to diabetes for men and women, respectively. In case 
of men’s mortality, there is an increasing pattern from age 
range 55–64 years onwards. Differences across countries 
are clear: the UK had the lowest mortality rate while France 
is the second best-off; the mortality rates for France were two 
times higher than the UK rates. At the age range 75+ years, 
Germany and Spain had very similar mortality rates. By far 
the highest value was for Italy, where more than 250 out 
of 100,000 men aged 75 years and over died from diabetes 
in 2010.
For women (Figure 2), diabetes mortality was quite low 
for the younger age ranges but there was a steep increment 
from 65–74 years to the 75+ years age range for France, 
Germany, Italy and Spain. For instance in Italy, the mortality 
rate went from 40 to 263 per 100,000 women.
These rates were used to obtain the YLL by using the 
average age of death per age group and LE for every age 
group. The full formula used for YLL calculation was derived 
from the World Health Organization (WHO) and Fox-Rushby 
and Hanson.10,12
Furthermore, for this study, the disability weights for 
the treated population were 0.033. It is assumed that 2.4% 
of the adult population 15 years old and over are not treated 
for their diabetes based on estimates by Hill et al; The dis-
ability weight applied for untreated diabetics was 0.012.36 
These disability weights were obtained from the Global BoD 
study.9 For children between 0–14 years old, it is assumed that 
this population was 100% treated since they almost always 
uniquely suffer from T1DM. For the sensitivity analysis, a 
disability weight of 0.07 was used for YLD calculation based 
on Stouthard et al and Mathers et al.37,38
Results
Detailed results of YLL, YLD, and DALY for 2010 are 
presented in Table 1. Estimates for France, Germany, Italy, 
Spain, and the UK were calculated as a rate per 1,000 inhabit-
ants (inh) in order to compare results between countries.
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Figure 1 Male mortality rates by age group in 2010.
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Figure 2 Female mortality rates by age group in 2010.
Overall, the relative burden of diabetes was shown to be 
the highest for Germany and Italy: their estimates were 5.9 
and 5.8 DALYs per 1,000 inh, respectively. On the contrary, 
the UK had the lowest value of total DALYs lost, at 2.94 
DALYs per 1,000 inh. In between these extremes, the nega-
tive impact of diabetes in France and Spain caused 3.70 and 
4.36 DALYs per 1,000 inh, respectively.
As has been mentioned, each component of the DALY 
reflects the health losses associated with diabetes. The YLD 
captures the decrease in full health and reflects the degree of 
disability. The YLL is the difference between the expected 
age at death (LE) and actual age at death (mortality due to 
diabetes). Differences between components of DALYs across 
countries can also be seen in Table 1. Regardless of sex, esti-
mates of YLL were greater than YLD for France,  Germany, 
Italy, and Spain; in contrast, YLDs were greater than YLLs 
for the UK. The differences were driven by the values of YLL 
for both sexes. For instance, for men, although YLDs values 
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Table 1 YLLs (men and women), YLDs (men and women), and DALYs lost (men, women, and total) due to diabetes in the five EU 
countries of interest including inhabitants of all ages in 2010
 YLL  
men
YLL  
women
YLD  
men
YLD  
women
DALYs lost  
men
DALYs lost  
women
Total 
DALYs lost
France 2.20 2.32 1.59 1.29 3.80 3.61 3.70
germany 3.02 3.64 2.35 2.64 5.37 6.28 5.83
italy 3.57 4.58 1.73 1.78 5.30 6.35 5.84
spain 2.09 2.88 1.89 1.86 3.98 4.74 4.36
UK 1.08 0.97 2.08 1.74 3.17 2.71 2.93
Notes: Disability weights for treated and untreated are 0.07. Yll, YlD, and DalY are per 1,000 inhabitants.
Abbreviations: DalYs, disability-adjusted life years; EU, European Union; YlDs, years lived with disability; Ylls, years of life lost.
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Figure 3 DalY losses due to diabetes per 1,000 men by age.
Abbreviation: DalYs, disability-adjusted life years.
could be considered that follow a similar pattern, the UK has 
one-third of Germany’s YLL. Indeed, the difference between 
the highest and the lowest YLD was 0.49, while the disparity 
in YLL values was 2.49 points. This suggests that there is a 
higher burden caused by mortality due to diabetes for France, 
Germany, Italy, and Spain, whereas in the UK, the burden due 
to disability was higher.
The last three columns contain DALYs for countries of 
interest for women and men. The smallest value of DALY 
was seen for women in the UK. Differences in DALY values 
indicate that the burden of diabetes was higher for women 
compared to men in Germany, Italy, and Spain in 2010. For 
instance, Italian diabetic women lost one DALY more than 
Italian diabetic men. Conversely, DALYs in France and 
the UK were higher for men, suggesting a higher burden of 
diabetes for men compared to women in these two countries 
of interest.
The total number of DALYs per age group for men 
and women are shown in Figures 3 and 4, respectively. 
 Diabetes DALYs lost for men were very low for the younger 
age ranges, for all countries. However, in the UK, for those 
aged 35–44 years, the burden increased substantially, 
while diabetes DALYs remained low for the rest of these 
countries of interest. Diabetes was shown to consistently 
increase the burden of the disease across all age groups in 
France,  Germany, Italy, and Spain with the exception of the 
UK, whose burden did not start to expand again until the 
55–64 years age group upwards (Figure 3). 
Diabetes DALYs for women were very low for the 
younger age ranges in 2010 (Figure 4). The impact of dia-
betes continued quite constantly until the 45–54 years age 
group, after which diabetes burden became notable. Although 
increments of DALYs lost for the 45–54 and 65–74 years age 
groups were modest, diabetes burden increased heavily in the 
older age groups, for all five countries.
For all five countries, DALYs due to diabetes of the 
elderly population (65–74 and 75+ years) were divergent 
across countries for both men and women, which suggests 
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Figure 4 DalYs due to diabetes per 1,000 women by age (2010).
Abbreviation: DalYs, disability-adjusted life years.
Table 2 sensitivity analysis results
YLL  
men
YLD  
men
YLL  
women
YLD  
women
DALYs lost  
men
DALYs lost  
women
Total 
DALYs lost
France 2.20 3.38 2.32 2.73 5.59 5.05 5.32
germany 3.02 5.07 3.64 5.68 8.09 9.32 8.70
italy 3.57 3.73 4.58 3.82 7.30 8.40 7.90
spain 2.09 4.07 2.88 4.00 6.15 6.88 6.50
UK 1.08 4.49 0.97 3.75 5.57 4.72 5.10
Note: Yll, YlD, and DalY are per 1,000 inhabitants.
Abbreviations: DalYs, disability-adjusted life years; YlDs, years lived with disability; Ylls, years of life lost.
that burden of the disease is quite different across countries 
for the oldest groups. Indeed, the UK’s values were almost 
one-third of the DALYs in Germany. The increasing number 
of DALYs along with older ages might be explained due to 
the increasing prevalence and mortality of diabetes in older 
age groups (Figures 1 and 2). Thus, it is straightforward to 
distinguish different patterns: Italy, Germany, and Spain had 
a steep increment in diabetes burden as age increases, while 
the UK was shown to have the mildest burden, and France 
was in between the two trends.
sensitivity analysis of disability weights
In the sensitivity analysis, the disability weight used was 
0.07 for the treated and untreated diabetics;25 the results are 
shown in Table 2. This value represents a higher severity of 
diabetes compared to previous disability weights. This fact is 
reflected in the DALYs estimates: the loss of DALYs due to 
diabetes was higher for all countries in comparison with the 
base case. Germany has the largest DALY lost and the UK 
has the smallest lost. The ranking is unaltered: Germany has 
the highest DALY loss, Italy is the second worse-off, the third 
position was held by Spain, and the fourth and fifth positions 
were held by France and the UK, respectively. Despite the 
unaltered burden ranking, Germany also has the biggest dif-
ference if we compared estimates of the sensitivity analysis 
and the base case (2.87 DALY per 1,000 inh). The second 
biggest difference was for the UK, which had 2.17 DALYs 
extra per 1,000 inh. The smallest difference was for France, 
with a difference of only 1.6 DALY lost per 1,000 inh.
Discussion
The present study provides a reliable image of the burden 
of diabetes for France, Germany, Italy, Spain, and the UK 
in 2010 according to the methodology by the WHO.19,20 
We provide estimates on diabetes itself, not based on the 
comorbidities due to diabetes. The approach used presents a 
broad insight of the burden of this condition because it makes 
comparison between countries feasible.
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Using the H-DALY method, with incidence YLLs and 
prevalence YLDs, DALYs due to diabetes were the highest 
in Germany and the lowest in the UK. The major part of 
the burden was caused by premature mortality in France, 
 Germany, Italy, and Spain. However, disability due to dia-
betes was shown to be the primary contributor to the burden 
for the UK. A possible explanation for the lowest DALY due 
to diabetes in the UK could be that the age-specific mortality 
has been decreasing, with considerably fewer numbers of 
deaths due to diabetes from the age of 65 years in men and 
women compared to the mortality rates of the other coun-
tries of interest. Further, given that YLDs are quite similar 
across countries, the results suggest that diabetes is better 
managed in the UK, avoiding fatal events associated with 
this  condition. Given these results, to determine in which 
country the burden of diabetes was the largest, DALYs 
seemed necessary since the burden is not mainly driven by 
epidemiological frequency (mortality).
Additionally, it was possible to compare the burden of 
diabetes in men and women. Estimates showed that the bur-
den of diabetes is higher in men compared to women. Overall, 
men had a higher number of DALYs (46.46 per 1,000) com-
pared to women (35.52 per 1,000) despite the steep increase 
in the number of DALYs in women from 75+ years.
Regarding the methodological aspects, H-DALYs have 
the advantage of avoiding both the polio and Elvis problems, 
and only YLLs were calculated from an incidence perspec-
tive, which makes it easy to choose death as the event and 
connect all YLLs to the moment of death.20 All the data 
needed to calculate H-DALYs can be measured at the time 
in question, so these DALYs are a true period measure. 
There are limitations to these estimates. Firstly, the avail-
ability of input data conditioned our analysis. Prevalence data 
were not directly available for all districts from one national 
statistics database in the UK. Therefore, prevalence data were 
taken from different sources and adjusted to the  relevant age 
categories. In case prevalence information was missing for 
an age category, it was estimated based on the mean preva-
lence of an equivalent age category from another country 
of interest.
Secondly, disability weights were equal for all age catego-
ries and for both sexes as no direct QoL data were available to 
obtain individual disability weights that could have affected 
YLDs. In general, diabetes might be perceived differently at 
different ages,39 which could vary the  estimates. Therefore, 
either different disability weights should be applied for each 
age range or age weighting should be  introduced. Both alter-
natives are controversial, and so far, there is no agreement 
of consistent estimates of potential weights (Murray and 
Acharya, 1996; Anand and Hanson, 1997). Moreover, in this 
study, a sensitivity analysis was performed with alternative 
disability weights, which was shown to vary results signifi-
cantly, and estimates indicate a greater burden of diabetes 
for all countries included in this analysis.
Thirdly, the assumptions of this study are consistent with 
Hill et al, whose estimates suggested that 2.4% of diabetics 
in the US are not being treated.36 We were aware that this 
percentage might be different due to region-specific char-
acteristics though.
The estimates of DALYs from this study for treated and 
untreated patients are pooled in a single number and further 
research is needed in order to estimate more specific DALYs, 
since diabetes is a heterogeneous disease.
Results of this study suggest that mortality due to dia-
betes has been postponed until older ages in most cases. 
While the burden of diabetes due to premature death was 
still significant in 2010, it is also important to remark the 
substantial burden of diabetes whose medical consequences 
lead to disability problems. Therefore, greater allocation of 
resources to prevent diabetes or to reduce its impact on QoL 
may be necessary in the upcoming years.
Conclusion
This study estimated the burden of diabetes for France, 
 Germany, Italy, Spain, and the UK in 2010 by using the 
H-DALY method. The results show that Germany has the 
highest number of total DALYs lost, with a rate of 5.9 for 
2010 in their population due to diabetes, while the UK has the 
lowest number of DALYs due to diabetes. With reference to 
the male population, diabetes health loss estimates show that 
Germany has the highest number of DALYs, while the UK 
had the lowest number of DALYs. These results are equivalent 
for the female population: Germany had the biggest burden 
measured by 9.32 DALYs due to diabetes and the UK had 
4.72 DALYs, which were also the lowest compared to the 
other countries of interest.
Furthermore, DALYs lost to diabetes for men and 
women are relatively lower at younger ages and signifi-
cantly increase from the 35–44 years age group in all the 
populations of the countries of interest. This pattern may 
be explained by the increasing prevalence and mortality of 
diabetes among the older age groups. It is worth mention-
ing that for all countries except for the UK, a significant 
increase in DALYs lost to diabetes in women is observed 
for the 75 years and over population, which may lead to a 
higher burden of diabetes for the national health system 
due to a higher likelihood of elderly women in developing 
comorbidities at these ages.
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DALYs have been increasingly cited as a powerful tool to 
estimate the burden of different conditions and these results 
could be useful for the policy making process, since DALYs 
seem to be a necessary measure to determine which country 
has the largest burden of diabetes. However, as for other 
measures, DALYs should not be used as a cookbook recipe 
to implement public policies.
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